Compare KLAC & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLAC | NVS |
|---|---|---|
| Founded | 1975 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.0B | 286.5B |
| IPO Year | 1994 | N/A |
| Metric | KLAC | NVS |
|---|---|---|
| Price | $244.51 | $153.37 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 5 |
| Target Price | ★ $1,651.00 | $144.00 |
| AVG Volume (30 Days) | ★ 4.9M | 1.7M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | 0.42% | ★ 2.16% |
| EPS Growth | ★ 49.75 | N/A |
| EPS | ★ 26.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.45 | $2.30 |
| Revenue Next Year | $22.33 | $5.27 |
| P/E Ratio | ★ $10.24 | $23.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $236.00 | $112.34 |
| 52 Week High | $2,431.29 | $170.46 |
| Indicator | KLAC | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 23.28 | 56.42 |
| Support Level | $236.00 | $149.49 |
| Resistance Level | $1,179.40 | $154.57 |
| Average True Range (ATR) | 91.30 | 2.25 |
| MACD | -184.37 | 0.19 |
| Stochastic Oscillator | 0.33 | 85.62 |
KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.